Acquisitions - Purchase Price Allocation (Details) - Elusys Therapeutics - USD ($)	8 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2023	Apr. 18, 2022
Purchase price allocation:
Cash and cash equivalents					$ 5,719,899
Contract receivables					24,526,232
Prepaid expenses and other current assets					1,818,278
Inventory					5,844,000
Intangible asset - definite-lived (Note 7)					9,700,000
Property and equipment					50,224
Operating lease right of use assets					352,906
Other assets					1,329,153
Total assets acquired					49,340,692
Accounts payable					(204,794)
Accrued expenses and other current liabilities					(5,155,363)
Operating lease obligations					(352,906)
Deferred income tax liability					(3,644,120)
Other liabilities					(1,002,904)
Total liabilities assumed					(10,360,087)
Net assets acquired and liabilities assumed					38,980,605
Goodwill	$ 3,301,959		$ 3,301,959	$ 3,900,000	3,873,080
Total purchase consideration					$ 42,853,685
Total revenue of acquiree from acquisition date	6,000,000.0	$ 6,700,000
Net loss before income taxes of acquiree from acquisition date	$ 5,600,000	$ 5,000,000.0
Acquisition costs			$ 600,000